These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A case of pulmonary thromboembolism in thalassemia intermedia: are these patients at risk for thrombotic events? Ciceri L; Amato M; Cappellini MD; Fiorelli G Ann Ital Med Int; 2000; 15(3):218-20. PubMed ID: 11059063 [TBL] [Abstract][Full Text] [Related]
24. Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation. Toulon P; Abecassis L; Smahi M; Ternisien C Thromb Res; 2010 Dec; 126(6):536-42. PubMed ID: 20950840 [TBL] [Abstract][Full Text] [Related]
25. Monitoring heparin therapy with the activated partial thromboplastin time. Stuart RK; Michel A Can Med Assoc J; 1971 Mar; 104(5):385-8. PubMed ID: 5557913 [TBL] [Abstract][Full Text] [Related]
26. [Strategies for utilization of anticoagulants in pulmonary embolism]. Fartoukh M; Simonneau G Rev Mal Respir; 1999 Nov; 16(5 Pt 2):949-60. PubMed ID: 10907444 [TBL] [Abstract][Full Text] [Related]
27. Recent advances in search of oral heparin therapeutics. Paliwal R; Paliwal SR; Agrawal GP; Vyas SP Med Res Rev; 2012 Mar; 32(2):388-409. PubMed ID: 21287569 [TBL] [Abstract][Full Text] [Related]
28. Intravenous anticoagulants: heparin and ancrod. Drug Ther Bull; 1972 Apr; 10(8):29-30. PubMed ID: 5038790 [No Abstract] [Full Text] [Related]
29. Interpretation of coagulation test results under direct oral anticoagulants. Mani H Int J Lab Hematol; 2014 Jun; 36(3):261-8. PubMed ID: 24750672 [TBL] [Abstract][Full Text] [Related]
30. Anticoagulant therapy: through a glass darkly. Hampton JW Am Fam Physician; 1974 Feb; 9(2):100-4. PubMed ID: 4810867 [No Abstract] [Full Text] [Related]
31. [Control of heparin and oral anticoagulants, with micromethods: thrombin time, quick determination with addition of protamine]. Seiler K; Müller G; Duckert F Schweiz Med Wochenschr; 1970 Sep; 100(36):1522-8. PubMed ID: 5524716 [No Abstract] [Full Text] [Related]
32. [Quality control in the coagulation laboratory with special reference to conventional methods for control of oral anticoagulant therapy]. Paar D Med Lab (Stuttg); 1981; 34(3):83-7. PubMed ID: 7231352 [No Abstract] [Full Text] [Related]
33. Anticoagulants in venous thromboembolism. Prophylactic and therapeutic use. Hirsh J; Gallus AS Postgrad Med; 1974 Jan; 55(1):211-7. PubMed ID: 4588719 [No Abstract] [Full Text] [Related]
34. Monitoring effects of oral anticoagulants during treatment with heparin. Thomas P; Fennerty A; Backhouse G; Bentley DP; Campbell IA; Routledge PA Br Med J (Clin Res Ed); 1984 Jan; 288(6412):191. PubMed ID: 6419853 [No Abstract] [Full Text] [Related]
35. Kinetics of the anticoagulant effect of heparin. Estes JW JAMA; 1970 Jun; 212(9):1492-5. PubMed ID: 5467541 [No Abstract] [Full Text] [Related]
36. [Anticoagulant, fibrinolytic and antithrombotic effects of the heparin-insulin complex]. Liapina LA; Pastorova VE Izv Akad Nauk Ser Biol; 2002; (6):710-3. PubMed ID: 12561334 [TBL] [Abstract][Full Text] [Related]
37. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415 [TBL] [Abstract][Full Text] [Related]